A Study on the Latest Results of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer Utilising PD-1 Monoclonal Antibody in Combination with Platinum Antineoplastic Agent and Tegafur Chemotherapy

Objective: To investigate the efficacy and safety of programmed cell death receptor1 (PD-1) monoclonal antibody combined with platinum antineoplastic agent + tegafur for neoadjuvant chemotherapy of locally advanced gastric cancer. Methods: Clinical data of 53 patients with locally advanced gastric cancer adenocarcinoma (cT3-4aNxM0) who received preoperative neoadjuvant chemotherapy from 2018 to March 2023 at the Second Affiliated Hospital of Anhui Medical University were retrospectively analyzed. Based on whether PD-1 was used or not, they were divided into the control group and the observation group. The control group (n = 28) was treated with platinum (oxaliplatin/lobaplatin/cisplatin) + tegafur regimen, and the observation group (n = 25) was treated with the addition of a PD-1 inhibitor (Carelizumab in 12 cases/Sintilimab in 13 cases) on top of the control group. All of them were treated with 3 cycles of preoperative chemotherapy. The clinical efficacy and adverse reactions of the two groups were compared. The clinical characteristics of patients who underwent D2 standard radical surgery were compared: R0 resection rate, tumor regression grade, major pathologic response (MPR) rate, etc. The risk factors affecting MPR were then explored by univariate and multivariate regression analysis. Results: The